hepat
viru
hav
major
caus
enter
transmit
hepat
worldwid
pose
global
burden
estim
million
infect
million
result
symptomat
ill
viru
transmit
mainli
close
contact
infect
individu
consumpt
contamin
food
drink
water
extrem
environment
stabil
hav
particl
contribut
significantli
hav
epidemiolog
correl
poor
hygien
live
condit
consequ
virtual
everi
adult
develop
countri
seroposit
due
childhood
infect
contrari
region
improv
hygien
standard
infect
often
postpon
later
age
addit
diseas
sever
gener
infect
usual
mild
asymptomat
young
children
wherea
older
age
hepat
frequent
present
classic
symptom
acut
hepat
eg
jaundic
fatigu
gener
malais
etc
higher
incid
fulmin
hepat
may
requir
liver
fulmin
hepat
occur
especi
age
mortal
rate
addit
hav
superinfect
chronic
liver
diseas
patient
eg
hepat
b
c
believ
increas
morbid
although
find
still
subject
sinc
highli
effici
vaccin
provid
immun
becom
avail
hav
mortal
morbid
decreas
howev
occasion
outbreak
hepat
sometim
result
fatal
outcom
still
occur
industri
countri
instanc
last
decad
outbreak
link
consumpt
contamin
green
onion
semidri
tomato
seafood
raw
oyster
sushi
posit
research
interest
molecular
biolog
pathogenesi
hav
decreas
substanti
sinc
avail
safe
effici
vaccin
nonetheless
hav
remain
intrigu
poorli
understood
viru
hepat
still
public
health
problem
mani
countri
review
key
aspect
biolog
hav
emphasi
recent
find
uniqu
characterist
viru
potenti
clinic
use
antivir
hav
discuss
well
hav
cellular
receptor
identifi
african
green
monkey
kidney
cell
agmk
attach
probabl
function
consequ
human
homolog
identifi
character
human
hav
also
known
marker
acut
ischem
kidney
injuri
context
refer
kidney
injuri
molecul
regul
base
immun
context
refer
immunoglobulin
mucin
protein
nevertheless
sinc
also
express
like
addit
receptor
requir
hav
attach
entri
instanc
suggest
promot
hav
entri
without
function
addit
iga
report
mediat
infect
hepatocyt
via
asialoglycoprotein
receptor
asgpr
fact
iga
also
identifi
natur
ligand
may
explain
hav
enter
hepatocyt
asgpr
therebi
promot
enterohepat
circul
continu
endogen
reinfect
phenomenon
thought
play
essenti
role
prolong
relaps
case
hepat
emerg
avid
igg
antibodi
break
cycl
eventu
clear
follow
bind
cell
surfac
hav
particl
intern
suggest
occur
endocytosi
sinc
hav
infect
inhibit
blocker
endosom
acidif
monensin
ammonium
chlorid
howev
precis
mechan
remain
unclear
date
upon
bind
receptor
particl
destabil
thu
initi
uncoat
process
releas
rna
host
cell
uncoat
report
slow
asynchron
process
report
durat
hr
contrast
hour
propos
asynchron
may
due
fact
hav
inoculum
contain
heterogen
mixtur
matur
virion
provirion
provirion
still
requir
matur
cleavag
discuss
follow
entri
prior
uncoat
might
therefor
uncoat
slowli
matur
uncoat
process
dens
noninfecti
hav
uncoat
intermedi
form
intriguingli
particl
appear
alter
sediment
profil
therebi
differ
typic
picornavir
final
low
ph
ion
report
play
import
role
hav
receptor
bind
uncoat
matur
cleavag
provirion
follow
viru
entri
describ
upon
complet
uncoat
rna
releas
host
cell
unknown
mechan
viral
rna
releas
cytoplasm
translat
singl
polyprotein
similar
picornavirus
hav
employ
ire
locat
utr
direct
translat
viral
genom
use
host
ribosom
machineri
picornavirus
affect
host
cell
protein
synthesi
favor
effici
translat
viral
mrna
process
mediat
proteolyt
cleavag
eukaryot
initi
factor
therebi
induc
complet
shutdown
cap
mrna
intriguingli
unlik
picornavirus
thought
hav
ire
depend
part
intact
fact
hav
compet
intact
host
cell
machineri
may
also
explain
poor
replic
cell
cultur
see
section
howev
recent
public
redondo
et
al
suggest
hav
translat
occur
without
intact
anoth
factor
may
crucial
next
translat
polyprotein
process
posttransl
seri
proteolyt
cleavag
sever
function
precursor
matur
protein
primari
posttransl
cleavag
occur
junction
instead
junction
picornavirus
fig
process
step
except
junction
discuss
mediat
function
precursor
differ
picornavirus
may
use
lpro
intriguingli
hav
protein
unlik
picornavirus
proteolyt
activ
contain
seem
implic
morphogenesi
see
section
f
sinc
translat
viral
protein
rna
replic
compet
process
must
balanc
properli
allow
effici
viral
order
tip
balanc
translat
replic
poli
protein
pabp
part
complex
cleav
hav
cleavag
product
pabp
shown
improv
capac
compar
uncleav
pabp
may
act
domin
neg
translat
thu
favor
viral
rna
addit
proteolyt
cleavag
poli
rc
protein
interact
tract
hav
may
also
implic
regul
balanc
translat
viral
rna
enzym
bind
hav
ire
polypyrimidin
tract
bind
protein
ptb
glyceraldehyd
dehydrogenas
la
autoantigen
respect
enhanc
suppress
suppress
rna
virus
replic
viral
genom
take
place
replic
complex
consist
rearrang
cellular
membran
contain
viral
host
protein
studi
reveal
import
role
precursor
protein
membran
rearrang
form
replic
complex
complex
describ
tubular
vesicular
network
thought
endoplasmat
reticulum
er
howev
recent
public
describ
mitochondri
local
precursor
protein
suggest
hav
replic
complex
may
deriv
outer
mitochondri
line
hypothesi
exchang
transmembran
domain
polioviru
transmembran
domain
result
loss
replic
within
replic
complex
viral
genom
transcrib
antisens
rna
subsequ
serv
templat
product
new
viral
genom
process
protein
function
rna
polymeras
vpg
protein
serv
start
point
transcript
coval
link
genom
end
conserv
replic
element
near
end
sequenc
like
direct
uridylyl
vpg
way
prime
vpg
initi
rna
replic
junction
remain
uncleav
transmembran
protein
serv
anchor
tether
grow
hav
rna
strand
associ
protein
membran
replic
case
also
report
protein
hav
bind
end
antisens
rna
way
protein
may
implic
anchor
neg
sens
rna
templat
membran
replic
despit
fact
multiti
capsid
assembl
process
poorli
understood
hav
differ
variou
step
picornavirus
follow
initi
cleavag
junction
discuss
part
protein
coordin
proper
fold
precursor
protein
precursor
protein
process
stabl
precursor
consist
px
precursor
consist
matur
build
block
assembl
pentam
subsequ
associ
viral
rna
form
preprovirion
final
process
step
cleav
precursor
px
yield
matur
viru
particl
protein
process
px
mediat
yet
unknown
cellular
although
cleavag
perform
extracellular
enzym
like
factor
xa
matur
also
execut
lysosom
proteinas
cathepsin
l
may
indic
role
lysosom
proteinas
matur
cleavag
potenti
target
hav
provirion
earli
lysosom
matur
hand
process
thought
process
depend
presenc
encapsid
result
rather
small
compar
picornavirus
lack
myristoyl
note
matur
protein
never
identifi
purifi
viru
stock
role
capsid
format
remain
hav
enter
transmit
viru
replic
mostli
hepatocyt
excret
via
bile
faec
despit
fact
exact
detail
hav
releas
remain
elus
mechan
seem
differ
depend
cell
type
infect
thought
involv
either
cellular
protein
transport
pathway
special
hepatocellular
transport
protein
involv
bile
blank
colleagu
demonstr
follow
infect
polar
human
intestin
epitheli
cell
releas
progeni
viru
larg
restrict
apic
way
viru
secret
mainli
intestin
lumen
result
amplif
hav
inoculum
intestin
thu
increas
viral
shed
spread
viru
howev
still
unclear
mechan
hav
reach
blood
stream
role
transcytosi
cell
present
peyer
patch
ileum
suggest
mechan
found
polioviru
reoviru
anoth
studi
describ
infect
polar
human
hepatocyt
occur
effici
via
basolater
plasma
membran
progeni
viru
export
basolater
membran
bloodstream
rather
apic
membran
bile
channel
contrast
vivo
observ
bile
faecal
titer
consider
higher
serum
reuptak
transcytosi
progeni
viru
hepatocyt
bile
channel
suggest
mechan
enter
secret
hav
nonenvelop
icosahedr
particl
approxim
nm
matur
capsid
compos
pentam
consist
five
copi
unlik
picornavirus
appear
present
matur
hav
particl
see
section
f
attempt
produc
imag
hav
particl
remain
unsuccess
far
show
imag
obtain
microscopi
suggest
absenc
canyon
surround
fivefold
axi
way
differ
picornavirus
howev
result
confirm
publish
separ
date
hav
limit
number
neutral
antigen
site
immunodomin
antigen
site
compos
residu
second
antigen
site
glycophorin
bind
site
hav
bind
erythrocyt
caus
hemagglutin
process
optim
acid
ph
impair
physiolog
ph
suggest
hav
evolv
escap
erythrocyt
bind
consequ
inde
mutant
bind
site
display
increas
clearanc
blood
lower
overal
fit
suggest
evolutionari
constraint
explain
low
level
antigen
variabl
glycophorin
bind
one
evas
tactic
ablat
innat
immun
alarm
system
induc
ifn
express
hav
shown
inhibit
rna
ds
rna
gene
interf
retino
gene
melanoma
gene
signal
pathway
fig
recogn
rna
detect
picornavir
rna
coval
link
use
adaptor
protein
call
mitochondri
antivir
signal
protein
mav
also
known
visa
cardif
local
outer
membran
upon
activ
mav
recruit
activ
kinas
inhibitor
kinas
respons
phosphoryl
ifn
regulatori
factor
eventu
lead
dimer
nuclear
transloc
induct
transcript
hav
protein
describ
interfer
mav
therebi
disrupt
innat
cellular
antivir
defens
mechan
precursor
protein
stabl
polyprotein
process
intermedi
requir
domain
cleavag
inactiv
mav
transmembran
domain
protein
ascertain
mitochondri
local
catalyt
site
perform
actual
proteolyt
cleavag
mav
mere
lack
domain
incap
perform
addit
demonstr
protein
suppress
mav
function
kinas
activ
thu
synergist
suppress
signal
although
exact
mechan
still
remain
receptor
provid
addit
recognit
mechan
dsrna
activ
also
result
phosphoryl
induct
transcript
unlik
downstream
action
mediat
trif
receptor
adaptor
induc
activ
kinas
recent
studi
report
proteolyt
cleavag
trif
analog
specif
cleavag
mav
without
domain
capabl
perform
cleavag
suggest
sequenc
requir
modifi
substrat
specif
without
requir
catalyt
polymeras
activ
addit
proteolyt
cleavag
trif
perform
cleavag
trif
mav
report
picornavirus
well
exampl
coxsackieviru
mav
trif
enteroviru
trif
unlik
hav
virus
appear
suffici
proteolysi
interestingli
mav
trif
also
cleav
hcv
proteas
despit
fact
hav
hcv
proteas
differ
cleavag
specif
phylogenet
unrel
target
pair
adaptor
protein
may
consid
remark
exampl
converg
second
immun
evas
strategi
employ
hav
found
codon
bia
nonuniform
usag
codon
due
lack
mechan
induc
cellular
shut
hav
compet
host
mrna
translat
describ
within
context
hav
strateg
adopt
codon
bia
toward
rare
codon
result
highli
deoptim
code
phenomenon
contribut
consider
low
replic
effici
hav
sever
way
seem
serv
multipl
purpos
first
deoptim
codon
use
may
reflect
strategi
rare
trna
prefer
abund
trna
therebi
avoid
competit
cellular
trna
absenc
adequ
host
cell
translat
shut
second
due
decreas
translat
replic
rate
viru
capabl
keep
cellular
amount
dsrna
minimum
thu
escap
host
cell
antivir
addit
codon
particularli
suppress
hav
code
particular
codon
deoptim
propos
associ
recognit
unmethyl
cpg
innat
immun
pathogen
marker
contrari
methyl
cpg
pair
host
also
way
hav
evad
attent
immun
system
third
use
rare
codon
usual
group
cluster
import
translat
kinet
cluster
may
lead
transient
translat
stop
phenomenon
known
ribosom
suggest
transient
stop
may
import
prerequisit
proper
fold
hav
structur
protein
therebi
contribut
low
antigen
variabl
extrem
environment
stabil
consequ
hav
adapt
replic
vitro
circumst
chemic
induc
cellular
shut
result
strain
code
sequenc
display
reduc
environment
given
prefer
hav
reduc
rna
replic
translat
level
comprehens
hav
would
employ
ineffici
type
iii
effici
ire
would
compat
escap
innat
immun
mani
ribosom
stall
conclus
code
bias
found
hav
genom
may
result
evolutionari
pressur
toward
environment
stabil
thu
control
translat
kinet
obtain
resili
viral
particl
ii
evad
host
immun
addit
insight
mechan
action
would
prove
valuabl
regard
understand
viru
evolut
interplay
addit
manipul
innat
immun
hav
also
modifi
adapt
immun
receptor
bind
phosphatidylserin
ptdser
receptor
function
potent
costimulatori
molecul
regul
activ
toler
induct
thu
suppress
autoimmun
respons
recent
studi
report
constitut
express
regulatori
treg
function
special
cell
limit
magnitud
immun
respons
divers
pathogen
way
avoid
hyperact
immun
respons
subsequ
collater
tissu
sever
microorgan
activ
treg
order
limit
inflamm
tissu
injuri
case
chronic
hbv
hcv
convers
bind
hav
receptor
inhibit
treg
cell
way
host
overwhelm
sinc
treg
cell
normal
suppress
autoimmun
reaction
allow
hav
escap
attent
immun
system
addit
hav
inhibit
product
transform
growth
factor
treg
cell
therebi
block
respons
complementari
hav
stimul
product
limit
liver
taken
togeth
inhibit
treg
function
hav
creat
environ
favor
viral
replic
establish
infect
find
may
also
provid
explan
hav
may
elicit
autoimmun
hepat
extrahepat
manifest
includ
autoimmun
hemolyt
anemia
even
though
complic
hygien
hypothesi
state
upris
atop
diseas
includ
asthma
allerg
rhiniti
atop
dermat
industri
countri
due
increas
hav
serostatu
regard
hygien
marker
correl
atopi
studi
report
sever
group
hav
infect
neg
correl
hay
fever
asthma
atop
howev
studi
unabl
replic
addit
mcintir
et
al
describ
previou
hav
infect
may
protect
atopi
individu
carri
six
amino
acid
insert
design
gene
encod
present
popul
howev
recent
studi
fail
fulli
replic
addit
appear
increas
suscept
sever
hav
doubl
mechanist
basi
suggest
partial
explain
observ
hav
bind
effici
result
effect
receptor
ii
natur
killer
cell
express
long
form
cytolyt
thu
may
protect
atopi
predispos
sever
hav
infect
conclus
possibl
relationship
previou
hav
infect
protect
atop
diseas
polymorph
still
subject
debat
repres
interest
area
research
hav
truli
protect
effect
sever
question
address
infect
need
occur
childhood
vaccin
similar
effect
relationship
use
find
therapeut
target
atopi
insight
relationship
may
prove
crucial
combat
rise
atop
diseas
industri
countri
unlik
picornavirus
cultur
wt
hav
cell
cultur
proven
quit
challeng
strain
replic
margin
vitro
eg
refer
hav
adapt
growth
cell
cultur
serial
passag
process
introduc
cell
cultur
adapt
mutat
stepwis
viral
genom
mutat
found
region
especi
also
part
intriguingli
cell
cultur
adapt
mutat
result
hav
strain
highli
attenu
vivo
eg
refer
major
advanc
cultur
hav
select
cell
line
design
allow
genet
stabl
growth
wt
hav
without
accumul
cell
cultur
adapt
although
wt
hav
induc
cytopath
effect
cpe
cell
cultur
cytopath
strain
may
aris
prolong
serial
cpe
appear
cell
type
specif
mostli
found
monkey
kidney
cell
line
like
select
viru
strain
induc
apoptosi
ribosom
rna
degrad
rnase
consequ
caspas
interestingli
seem
possibl
induc
cpe
cell
cultur
adapt
noncytopath
strain
specif
condit
lower
temperatur
decreas
cell
densiti
human
similarli
observ
cpe
strain
genotyp
iiia
cell
condit
unpublish
result
alreadi
demonstr
effici
inhibit
replic
hav
human
embryo
cell
complet
clear
follow
five
passag
iuml
later
anoth
studi
report
effect
concentr
minim
concentr
requir
reduc
viru
replic
iuml
select
index
si
cytotox
concentr
addit
vitro
activ
case
studi
describ
vivo
efficaci
three
patient
fulmin
hepat
one
patient
sever
hepat
failur
due
hav
follow
treatment
million
unit
per
day
liver
function
amelior
four
patient
howev
addit
high
price
parenter
administr
clinic
use
ifn
associ
sever
side
effect
hamper
usag
less
develop
region
amantadin
initi
thought
inhibit
hav
increas
intravesicular
ph
howev
antivir
effect
requir
extend
incub
compar
lipophil
amin
eg
methylamin
dansylcadaverin
line
find
inhibit
hav
translat
later
report
mechan
action
moa
studi
confirm
moder
activ
amantadin
addit
increas
effect
observ
amantadin
combin
howev
addit
fairli
limit
effect
vitro
si
around
pharmacokinet
studi
demonstr
maximum
plasma
concentr
c
max
follow
multipl
dosag
scheme
well
report
limit
use
clinic
context
guanidin
hcl
protein
enteroviru
inhibitor
mix
result
report
earliest
public
detect
inhibit
group
found
moder
inhibit
around
follow
treatment
cho
colleagu
report
revers
inhibit
mm
also
report
enhanc
replic
convers
result
yi
et
al
report
strong
inhibit
viral
replic
concentr
low
sever
factor
may
explain
inconsist
data
mutat
differ
viral
genom
studi
specif
region
ii
cell
type
use
antivir
assay
iii
multipl
infect
moi
found
import
determin
antivir
iv
detect
method
employ
limit
inform
avail
compound
activ
earli
step
replic
cycl
block
probabl
function
inhibitor
viru
attach
receptor
atropin
mm
prove
moder
reduc
hav
replic
target
earli
step
hav
replic
cycl
well
attach
possibl
uncoat
due
toxic
limit
antivir
activ
clinic
potenti
compound
low
glycyrrhizin
aqueou
extract
licoric
root
si
subsequ
studi
suggest
inhibit
membran
penetr
put
addit
activ
glycyrrhizin
prove
also
activ
rel
larg
panel
virus
includ
hbv
hcv
hsv
hiv
sever
propos
mechan
action
review
fior
et
howev
glycyrrhizin
may
caus
pseudohyperaldosteron
due
effect
addit
compound
readili
metabol
follow
oral
intraven
administr
attain
plasma
concentr
consider
lower
report
hamper
clinic
use
treatment
patient
probabl
potent
small
molecul
report
thu
far
valu
nm
inhibit
cell
entri
viral
uncoat
posit
possibl
mechan
action
antivir
activ
hav
drug
also
found
effect
rhinovirus
polioviru
howev
fail
protect
volunt
experiment
rhinoviru
infect
administ
oral
rais
doubt
concern
vivo
efficaci
hav
well
earli
stage
inhibitor
includ
chlorpromazin
former
thought
block
endocytosi
vesicl
latter
inhibit
endosom
monensin
anoth
endosom
acidif
blocker
yield
minor
extens
inhibit
hav
replic
differ
addit
earli
stage
inhibitor
sever
hav
inhibitor
identifi
target
differ
step
intracellular
replic
process
includ
rna
synthesi
translat
capsid
assembl
howev
inform
precis
moa
limit
instanc
ribavirin
demonstr
moder
effect
show
select
index
around
improv
activ
report
pyrazofurin
orotidin
decarboxylas
inhibitor
develop
halt
due
toxic
interfer
nucleotid
metabol
protamin
reduc
hav
replic
suggest
function
rna
polymeras
addit
inhibitor
oxid
phosphoryl
glycolysi
inhibitor
identifi
inhibitor
hav
replic
unknown
inhibitor
includ
brefeldin
inhibitor
transport
protein
synthesi
respect
moder
activ
also
report
amphotericin
drug
use
fungal
infect
immunomodul
treatment
subacut
scleros
panenceph
respect
howev
data
avail
moa
recent
year
sever
new
compound
synthes
antivir
activ
remain
rather
paper
report
highli
potent
inhibitor
hav
replic
report
toxic
data
make
imposs
judg
whether
select
consider
effort
undertaken
ration
design
develop
inhibitor
hav
human
enteroviru
relat
coronaviru
proteas
enzym
topolog
compar
serin
proteas
fact
cystein
consequ
gener
research
strategi
introduc
group
catalyt
site
sever
proteas
inhibitor
develop
year
modifi
peptid
nonpeptid
analog
despit
fact
modifi
peptid
easier
design
mere
mimick
natur
proteas
substrat
nonpeptid
peptidomimet
inactiv
prefer
sinc
modifi
order
increas
stabil
cellular
gastrointestin
uptak
properti
difficult
attain
peptid
similar
approach
alreadi
appli
enteroviru
result
molecul
rupintrivir
halt
unsuccess
phase
ii
clinic
first
hav
inhibitor
develop
modifi
peptid
base
sequenc
serv
competitor
natur
peptid
substrat
base
find
peptidyl
aldehyd
monofluoromethylketon
fmk
inhibitor
resolv
crystal
structur
hav
complex
peptidyl
fmk
inhibitor
indic
inhibitor
coval
bind
catalyt
one
peptidyl
fmk
inhibitor
also
test
ex
vivo
shown
reduc
hav
replic
howev
cellular
uptak
appear
major
problem
addit
sever
azaglutamin
deriv
found
irrevers
peptid
hand
sever
nonpeptid
antagonist
report
well
asymetr
azodicarboxamid
found
irrevers
inhibitor
hav
hrv
serin
threonin
also
inhibit
hav
inhibitor
includ
monophenyl
pseudoxazolon
glycin
cathepsin
k
lastli
halopyridinyl
ester
report
potent
nonpeptid
hav
inhibitor
thu
far
low
although
recent
public
field
seem
focu
increasingli
hrv
coronaviru
would
wise
neglect
possibl
activ
potenti
futur
use
market
hrv
coronaviru
proteas
inhibitor
sever
hav
infect
rna
interfer
rnai
suggest
futur
treatment
sever
hav
small
interf
rna
sirna
target
nonstructur
gene
effect
block
inhibit
also
report
target
domain
iiic
v
hav
three
consecut
applic
sirna
day
result
infect
titer
reduct
persist
infect
cell
howev
resist
emerg
fairli
quickli
mutat
target
site
necessit
combin
differ
clinic
rnai
therapi
would
establish
treatment
infecti
diseas
would
interest
explor
hepat
howev
clinic
applic
rnai
current
still
experiment
stage
recent
report
develop
three
assay
screen
identifi
small
molecul
inhibitor
hav
cpe
reduct
assay
base
cell
cultur
adapt
strain
genotyp
ib
amend
screen
viru
yield
assay
genotyp
iiia
strain
develop
well
allow
confirm
character
antivir
activ
select
molecul
known
inhibitor
amantadin
use
valid
assay
use
assay
three
enteroviru
inhibitor
differ
target
evalu
activ
pleconaril
known
capsid
yield
unexpectedli
limit
activ
inhibit
rupintrivir
inhibitor
prove
enviroxim
direct
inhibitor
induc
resist
mutat
enteroviru
protein
inact
three
system
recent
identifi
essenti
host
factor
replic
strategi
enterovirus
follow
recruit
enteroviru
protein
organel
membran
environ
creat
promot
viral
rna
replic
observ
hav
protein
target
toward
outer
mitochondri
membran
instead
togeth
observ
lack
activ
enviroxim
two
differ
cell
suggest
kinas
activ
play
role
hav
replic
small
anim
model
would
addit
prerequisit
develop
valid
compound
host
rang
hav
restrict
human
sever
nonhuman
primat
exampl
tamarin
effort
undertaken
toward
develop
small
anim
model
exampl
viru
adapt
mous
cell
line
infect
guinea
howev
far
robust
model
clinic
hepat
avail
recent
found
chimer
mous
model
support
engraft
prolifer
transplant
human
hepatocyt
suscept
hav
infect
pang
person
commun
despit
fact
result
still
need
publish
could
repres
major
leap
forward
research
despit
fact
hepat
diseas
infect
usual
mild
continu
attent
pathogen
warrant
outbreak
occasion
case
fatal
fulmin
hepat
still
occur
age
infect
shift
upward
sever
infect
increas
well
morbid
mortal
may
also
increas
patient
chronic
liver
diseas
exampl
due
hbv
hcv
addit
recent
report
warn
potenti
emerg
taken
togeth
reason
warrant
continu
expans
current
vaccin
program
also
develop
antivir
drug
hav
even
though
may
particularli
interest
commerci
point
view
far
potent
select
inhibitor
report
therefor
propos
focu
antivir
effort
market
drug
antivir
current
clinic
develop
use
drug
would
much
appreci
therapi
fact
current
employ
cpe
reduct
assay
screen
librari
drug
promis
result
far
also
fundament
biolog
level
hav
remain
larg
understudi
viru
despit
mani
interest
featur
investig
could
provid
uniqu
insight
pathogenesi
tissu
tropism
determin
replic
strategi
hav
picornavirus
gener
